HomeCompareCYTR vs GBDC

CYTR vs GBDC: Dividend Comparison 2026

CYTR yields 11620.00% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYTR wins by $242484085295883776.00M in total portfolio value
10 years
CYTR
CYTR
● Live price
11620.00%
Share price
$0.09
Annual div
$10.46
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$242484085295883808.00M
Annual income
$238,447,405,964,682,430,000,000.00
Full CYTR calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — CYTR vs GBDC

📍 CYTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTRGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYTR + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYTR pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTR
Annual income on $10K today (after 15% tax)
$987,700.00/yr
After 10yr DRIP, annual income (after tax)
$202,680,295,069,980,070,000,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, CYTR beats the other by $202,680,295,069,980,070,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTR + GBDC for your $10,000?

CYTR: 50%GBDC: 50%
100% GBDC50/50100% CYTR
Portfolio after 10yr
$121242042647941920.00M
Annual income
$119,223,702,982,341,220,000,000.00/yr
Blended yield
98.34%
📊

Analyst Conviction Gap

Where Wall Street is split right now

CYTR
Analyst Ratings
6
Buy
1
Hold
Consensus: Buy
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTR buys
0
GBDC buys
0
No recent congressional trades found for CYTR or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTRGBDC
Forward yield11620.00%11.86%
Annual dividend / share$10.46$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$242484085295883808.00M$20.85M
Annual income after 10y$238,447,405,964,682,430,000,000.00$16,450,733.83
Total dividends collected$242216106432564192.00M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: CYTR vs GBDC ($10,000, DRIP)

YearCYTR PortfolioCYTR Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$1,172,700$1,162,000.00$12,492$1,791.70+$1.16MCYTR
2$128,607,817$127,353,028.04$16,527$3,160.58+$128.59MCYTR
3$13,190,478,160$13,052,867,796.09$23,588$5,904.90+$13190.45MCYTR
4$1,265,280,964,319$1,251,167,152,687.08$37,141$11,901.65+$1265280.93MCYTR
5$113,519,013,580,267$112,165,162,948,446.42$66,205$26,463.38+$113519013.51MCYTR
6$9,526,401,425,885,696$9,404,936,081,354,810.00$137,452$66,612.65+$9526401425.75MCYTR
7$747,812,665,514,758,900$737,619,415,989,061,100.00$342,372$195,298.53+$747812665514.42MCYTR
8$54,914,516,334,558,180,000$54,114,356,782,457,390,000.00$1,053,292$686,954.33+$54914516334557.13MCYTR
9$3,772,597,505,795,689,000,000$3,713,838,973,317,711,700,000.00$4,111,439$2,984,416.95+$3772597505795685.00MCYTR
10$242,484,085,295,883,800,000,000$238,447,405,964,682,430,000,000.00$20,849,974$16,450,733.83+$242484085295883776.00MCYTR

CYTR vs GBDC: Complete Analysis 2026

CYTRStock

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Full CYTR Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this CYTR vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTR vs SCHDCYTR vs JEPICYTR vs OCYTR vs KOCYTR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.